Evaluation of cardiovascular risk in a lung cancer screening cohort: what value does it bring?

Area of Science:

• Cardiology
• Pulmonology
• Oncology

Background:

• Lung cancer screening identifies individuals at high risk for lung cancer.
• Cardiovascular disease (CVD) is a leading cause of mortality in the general population and may be prevalent in lung cancer screening cohorts.
• Current lung cancer screening protocols do not routinely incorporate comprehensive CVD risk assessment.

Purpose of the Study:

• To evaluate the potential for improving cardiovascular disease (CVD) outcomes within lung cancer screening populations.
• To assess the feasibility of integrating a low-cost, noninvasive CVD risk assessment into existing lung cancer screening programs.

Main Methods:

• Review of existing literature on CVD prevalence in lung cancer screening cohorts.
• Analysis of current lung cancer screening protocols and assessment tools.
• Evaluation of low-cost, noninvasive methods for CVD risk stratification.

Main Results:

• Lung cancer screening cohorts represent a population with potentially high, undiagnosed CVD risk.
• Integrating a noninvasive CVD risk assessment alongside current screening methods is feasible.
• Such an integrated approach offers a significant opportunity to improve patient outcomes.

Conclusions:

• There is a substantial unmet need for CVD risk assessment in individuals undergoing lung cancer screening.
• A low-cost, noninvasive CVD risk assessment can be effectively integrated into lung cancer screening programs.
• This integrated approach holds promise for improving cardiovascular health and overall outcomes in this patient population.